Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409509 · ClinicalTrials.gov registry record · Phase 2
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
A Phase 2 study of Coronavirus Disease 2019 (COVID-19), sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 14
- Study locations
NCT04409509 is a Phase 2 study of Coronavirus Disease 2019 (COVID-19) that has completed, run by CSL Behring. The registered enrollment target is 124 participants. The trial reports 14 study locations across 10 states.
The verdict
NCT04409509, a Phase 2 study of Coronavirus Disease 2019 (COVID-19), has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Study Locations (14)
Florida
- Nova Clinical Research, LLC - Bradenton
- Theia Clinical Research, LLC - St. Petersburg
Iowa
- MercyOne North Iowa Medical Center - Mason City
- Northeast Iowa Medical Education Foundation - Waterloo
New Jersey
- Holy Name Hospital - Teaneck
- Inspira Health Center Vineland - Vineland
Texas
- PharmaTex Research - Amarillo
- UT Health Science Center, McGovern Medical School - Houston
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Mississippi
- University of Mississippi Medical Center - Jackson
New York
- Sisters of Charity Hospital/ St. Joseph's Campus - Buffalo
North Carolina
- Carolina Institute for Clinical Research - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409509
The ClinicalTrials.gov registry entry for NCT04409509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronavirus Disease 2019 (COVID-19) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04409509 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, Iowa, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04409509 about?
NCT04409509 is a clinical study titled "Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)". This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
What is the current status of trial NCT04409509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2020-07-01. Estimated completion is 2021-01-12.
What conditions does trial NCT04409509 study?
This clinical trial studies the following conditions: Coronavirus Disease 2019 (COVID-19).
What interventions are being tested in trial NCT04409509?
The interventions under investigation include: Placebo (DRUG), Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT04409509?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04409509 being conducted?
This trial has 14 study locations across Florida, Iowa, Massachusetts, Mississippi, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus Disease 2019 (COVID-19)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.